Now showing items 1-4 of 4

    • Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. 

      Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R (2018-07-20)
      ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ...
    • Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. 

      Wentzensen, N; Poole, EM; Trabert, B; White, E; Arslan, AA; Patel, AV; Setiawan, VW; Visvanathan, K; Weiderpass, E; Adami, H-O; Black, A; Bernstein, L; Brinton, LA; Buring, J; Butler, LM; Chamosa, S; Clendenen, TV; Dossus, L; Fortner, R; Gapstur, SM; Gaudet, MM; Gram, IT; Hartge, P; Hoffman-Bolton, J; Idahl, A; Jones, M; Kaaks, R; Kirsh, V; Koh, W-P; Lacey, JV; Lee, I-M; Lundin, E; Merritt, MA; Onland-Moret, NC; Peters, U; Poynter, JN; Rinaldi, S; Robien, K; Rohan, T; Sandler, DP; Schairer, C; Schouten, LJ; Sjöholm, LK; Sieri, S; Swerdlow, A; Tjonneland, A; Travis, R; Trichopoulou, A; van den Brandt, PA; Wilkens, L; Wolk, A; Yang, HP; Zeleniuch-Jacquotte, A; Tworoger, SS (2016-08)
      <h4>Purpose</h4>An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle ...
    • Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. 

      Miller, RE; Brough, R; Bajrami, I; Williamson, CT; McDade, S; Campbell, J; Kigozi, A; Rafiq, R; Pemberton, H; Natrajan, R; Joel, J; Astley, H; Mahoney, C; Moore, JD; Torrance, C; Gordan, JD; Webber, JT; Levin, RS; Shokat, KM; Bandyopadhyay, S; Lord, CJ; Ashworth, A (2016-07)
      New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based ...
    • Translational genomics of ovarian clear cell carcinoma. 

      Khalique, S; Lord, CJ; Banerjee, S; Natrajan, R (2020-04)
      Ovarian clear cell carcinomas (OCCC) are rare aggressive, chemo-resistant tumours comprising approximately 13% of all epithelial ovarian cancers, which have distinct clinical and molecular features, when compared to other ...